We are pleased to announce the appointment of industry experts Dr John Troyer Ph.D. and Dr Wenbin Lai, Ph.D., MBA to our Management and Operations advisory board.
Dr. Troyer will assume the role of Chief Operations and brings over twenty five years of experience in multiple aspects of biologics and drug development from discovery to registration and commercial operations in various companies such as Pharmathene and ICON PLC. Specifically, he has overseen over 36 INDs, NDAs, BLAs and supervised a variety of Orphan Drug and FDA Fast-track applications/regulatory filings. Dr Troyer obtained his BS from Old Dominion University and Ph.D. from Eastern Virginia Medical School.
Dr. Lai will assume the role of CMC (Chemistry, Manufacturing, and Controls) advisor having spent years handling process and product development activities, for portfolio vaccine products in the preclinical stage, progressing into clinical stages in various pharmaceutical companies. Dr. Lai obtained her Ph.D. from the University of Cambridge and a First Class Honours in B. Eng (Chemical) from the National University of Singapore. She later received her MBA from the Singapore Management University, where she graduated as valedictorian.
Together, these two industry veterans will lend their business, technology, and operational acumen to support the PathoVax team to develop and push forward our innovative programs.